About
Remepy is pioneering hybrid drugs, and redefining combination therapy. Its mission is to bring better personalized care to patients.
Remepy’s Digital molecules are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. Its Digital molecules include digitized, standardized, evidence-based interventions, designed to enhance brain plasticity and connectivity, balance the immune system, and drive behavioral changes. The company addresses disease end-points as well as side-effects and disease comorbidities.
Remepy partners with pharma companies to bring Hybrid Drugs to market that will combine Remepy’s Digital Molecule and traditional drug components.
Funding history · 4 rounds · $25.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Remepy's core business model?
- Remepy pioneers hybrid drugs by combining its 'Digital Molecules' (mobile applications with digital treatment protocols) with traditional drug components, partnering with pharmaceutical companies to bring these to market.
- When was Remepy founded and where is it headquartered?
- Remepy was founded in December 2021 and is headquartered in Ramat Gan, Israel.
- What was Remepy's first recorded funding round?
- In December 2022, Remepy secured a Seed funding round of $5 million, with Fresh Fund as a lead investor.
- Which investor led Remepy's $10 million Seed round in May 2024?
- NFX Capital led Remepy's $10 million Seed funding round in May 2024.
- What was the total amount raised by Remepy as of its latest funding information?
- According to startupim data, Remepy has raised a total of $25 million USD.
- What was a significant operational development for Remepy in February 2024?
- In February 2024, former Israeli Prime Minister Naftali Bennett joined Remepy's Board for its hybrid drug initiatives.
- What collaboration did Remepy announce in April 2026?
- In April 2026, Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany, to advance hybrid drugs across various therapeutic areas, including rare tumor programs.
- What was a key finding regarding Remepy's mobile app in June 2025?
- In June 2025, Remepy's mobile app was shown to rewire the brain, modulate the immune system, and improve mood in adults with subjective cognitive decline.
- What is Remepy's employee count?
- Remepy has 59 employees.